Olmesartan Medoxomil/Amlodipină Accord (Amlodipine)

Amlodipine, the active ingredient in Olmesartan Medoxomil/Amlodipină Accord, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil/Amlodipină Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil/Amlodipină Accord is used to manage high blood pressure by acting on the renin‑angiotensin system and vascular smooth muscle. - Hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk in adults.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and reddening of the skin. - Fatigue: feeling unusually tired. - Palpitations: awareness of heartbeats.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may impair breathing. - Severe hypotension: marked drop in blood pressure causing faintness. - Myocardial infarction: rare occurrence of heart attack. - Elevated liver enzymes: signs of hepatic stress. - Allergic reactions: rash, itching, or anaphylaxis.

Patients should be monitored regularly for blood‑pressure response and renal function. - Blood pressure monitoring: check regularly to avoid excessive lowering. - Renal function assessment: evaluate kidney parameters before and during therapy. - Electrolyte balance: watch for potassium changes, especially with concomitant diuretics. - Cardiovascular status: avoid in severe aortic stenosis or decompensated heart failure. - Hepatic impairment: dose adjustment may be needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Drug interactions may affect efficacy or safety. Major Interactions (Avoid): - Potassium‑sparing diuretics: increase risk of hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin): raise amlodipine plasma levels. - Lithium: heightened lithium toxicity. - Other potent vasodilators: may cause severe hypotension. - ACE inhibitors or ARBs combined with high‑dose potassium supplements: risk of electrolyte imbalance.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect. - Diuretics: may lead to electrolyte disturbances. - Antidiabetic agents: blood‑glucose control may need adjustment. - Beta‑blockers: additive blood‑pressure lowering. - St. John’s wort: may reduce amlodipine exposure.